Title: Pharmacodynamics Psych 223
1PharmacodynamicsPsych 223
2Lecture Outline
- Neurotransmitter receptors
- Neurons brief introduction
- Synapse brief introduction
- Receptors
- Ligand-receptor interactions
- Specificity
- Affinity
- Intrinsic activity
- Agonists antagonists
- Reversible/Irreversible
- Competitive/Noncompetitive
- Dose-response relationships
- Law of mass action
- Dose-response relationship
- ED50, TD50, LD50
- Efficacy/potency
- Competitive/noncompetitive
- Summation/potentiation
3The Neuron
Reconstruction of a neuron.
Cartoon of a neuron.
4The Neuron
Photo of a neuron.
http//www.encorbio.com/Album/pages/ChkNFH-neuron1
.htm
5The Neuron and Synapse
6The Synapse
Synapses are the connecting points between neurons
Close-up of view of various synapses
7The Synapse
Electron microscope picture of a synapse
8The Synapse and Neurotransmitters
- Release of neurotransmitter
- Exocytosis The action potential triggers
voltage gated Ca channels. Ca signals the
release of neurotransmitter through exocytosis.
9The Synapse and Release
- Release of neurotransmitter
- Exocytosis
- Release Neurotransmitter is spilled into the
synapse.
10The Synapse, Release and the Receptor
- Release of neurotransmitter
- Exocytosis
- Release
- Binding neurotransmitter binds to receptors on
the postsynaptic membrane.
http//www.blackwellpublishers.co.uk/matthews/nmj.
html
11The Receptor and Binding
PRE
Synaptic cleft
POST
12The Receptor and Binding
Chemicals (ligands) must bind to the receptor and
remain bound long enough for the receptor to be
activated.
PRE
Synaptic cleft
POST
13The Receptor - Specificity
Specificity ligands bind to specific receptors.
Not all ligands bind to all receptors.
PRE
Synaptic cleft
POST
14The Receptor - Specificity
There are a number of specific ligands and a
number of associated receptors.
PRE
Synaptic cleft
POST
15The Receptor Affinity
Affinity the extent to which the ligand is
capable of binding and remains bound to a
receptor. High Affinity the ligand binds well
and remains bound long enough to activate the
receptor. Low Affinity the ligand binds less
well and may not remain bound long enough to
activate the receptor.
16High Affinity Binding
High Affinity the ligand binds well and remains
bound long enough to activate the receptor.
PRE
Synaptic cleft
POST
17High Affinity Binding
Low Affinity the ligand binds less well and may
not remain bound long enough to activate the
receptor.
PRE
Synaptic cleft
POST
18The Receptor Intrinsic Activity
Intrinsic Activity the extent to which the
ligand activates the receptor. High Intrinsic
Activity the ligand produces a large effect on
the post synaptic cell. Low Intrinsic Activity
the ligand produces a small or inconsistent
effect on the post synaptic cell.
19High Affinity Binding
High Intrinsic Activity the ligand produces a
large effect on the post synaptic cell.
PRE
Synaptic cleft
POST
20High Affinity Binding
Low Intrinsic Activity the ligand produces a
small or inconsistent effect on the post synaptic
cell.
PRE
Synaptic cleft
POST
21Classes of Ligands
- Agonist
- High affinity
- High intrinsic activity
- Antagonist
- High affinity
- Low intrinsic activity
22Agonist
- High affinity
- High intrinsic activity
Agonist
23Antagonist
- High affinity
- Low intrinsic activity
Antagonist
24Classes of Ligands
- Antagonist
- Reversible can be unbound from the receptor.
- Irreversible cannot be unbound from the
receptor. - Competitive competes with other ligands for
biding to the receptor. - Non-competitive exerts its antagonist effects
without competition for occupancy of the
receptor.
25Reversible Antagonist
- High affinity
- Low intrinsic activity
Antagonist
26Irreversible Antagonist
- High affinity
- Low intrinsic activity
Irreversible Antagonist
27Competitive Antagonist
28Noncompetitive Antagonist
29Indirect Agonist
Indirect Agonist
30Law of Mass Action
D R
DR
Biological effect
- Drugs associate (bind) and dissociate (unbind)
from the receptors - With a fixed D and and a fixed R, DR will be
constant and the biological effect will be
constant. - If D is increased or decreased (more or less
drug), DR will increase or decrease
proportionately. - When all of the receptors are occupied (DR),
adding more D does not increase DR and there is
no further biological effect.
31Recap
- Specificity, affinity, intrinsic activity
- Agonists and Antagonists and their variants
- Affinity and intrinsic activity?
- Affect on the neuron and its biological effect
- Antagonists
- Reversible/nonreversible
- Competitive/noncompetitive
- Law of Mass Action
32Dose-Response Functions
Displays the relationship between the dose of a
ligand and some biological response to that
ligand.
Biological Effect
33Dose-Response FunctionED50
ED50 The dose at which 50 of the maximal
biological response is observed
Pain Relief
34Dose-Response FunctionTD5o
TD50 The dose at which 50 of the maximal
toxicity is observed
Toxicity
35Dose-Response FunctionLD50
LD50 The dose at which lethality is observed in
50 of subjects.
Lethality
36Dose-Response Function ED50 ,TD50 ,LD50
Percentage Responding
TD50
LD50
ED50
37Therapeutic IndexTD50/ED50
Percentage Responding
ED50
TD50
38Efficacy Potency
39Efficacy Potency
B
A
Biological Effect
Efficacy AB Potency AgtB
40Efficacy Potency
A
B
Biological Effect
Efficacy AgtB Potency AB
41Efficacy Potency
A
B
Biological Effect
Efficacy AgtB Potency AgtB
42Competitive and Noncompetitive Antagonists
43Competitive Antagonists
D R
Biological effect
DR
A R
No Biological effect
AR
Biological effect
D A R
DR
AR
D DA
DR DRAR
a
44Summation
B
A
AB
Biological Effect
45Potentiation
A
AB
Biological Effect
46Recap
- Dose-response relationships
- ED50, TD50, LD50
- Efficacy/potency
- Competitive/noncompetitive
- Summation/potentiation